Ann: Kazia paxalisib Phase II interim data, page-2

KAZIA’S PAXALISIB SHOWS POSITIVE OVERALL SURVIVAL SIGNAL
IN PHASE II GLIOBLASTOMA STUDY

Overall survival (OS) of 17.7 months, vs. 12.7 months for existing standard of care
Longest-treated patient remains progression-free 19 months after diagnosis

Sydney, 7 April 2020 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian
oncology-focused biotechnology company, is pleased to share positive interim data from its
ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common
and most aggressive form of primary brain cancer.
Key Points
• Interim analysis of Part A (escalation cohort) (n=9) showed median overall survival
(OS) of 17.7 months, representing a clinically meaningful extension of life when
compared to the 12.7 months associated with the existing standard of care,
temozolomide
• Interim analysis of all evaluable patients (Part A = 9; Part B = 21) shows median
progression-free survival (PFS) of 8.5 months, broadly in line with previous analysis,
and comparing favourably to the 5.3 months associated with temozolomide
• The longest-treated patient remains progression-free 19 months after diagnosis
• Approximately half the enrolled patients remain on drug and both OS and PFS figures
may further improve as the trial progresses toward conclusion
• Kazia expects to present further data in 2H CY2020 and final data in 1H CY2021